Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is an uncommon subtype of non-Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique clinicopathological features. Historically, patients with PMBCL were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy AE involved field radiation. Since a phase II trial, published in April 2013, demonstrated excellent results using dose-adjusted (DA) R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), this treatment has gained popularity. We performed a retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011. Patients were stratified by frontline regimen, R-CHOP versus DA-R-EPOCH. 132 patients were identified from 11 contributing centres (56 R-CHOP and 76 DA-R-EPOCH). The primary outcome was overall survival. Secondary outcomes included progression-free survival, complete response (CR) rate, and rates of treatment-related complications. Demographic characteristics were similar in both groups. DA-R-EPOCH use increased after April 2013 (79% vs. 45%, P < 0Á001), and there was less radiation use after DA-R-EPOCH (13% vs. 59%, P < 0Á001). While CR rates were higher with DA-R-EPOCH (84% vs. 70%, P = 0Á046), these patients were more likely to experience treatment-related toxicities. At 2 years, 89% of R-CHOP patients and 91% of DA-R-EPOCH patients were alive. To our knowledge, this represents the largest series comparing outcomes of R-CHOP to DA-R-EPOCH for PMBCL.
Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a unique subtype of aggressive B-cell non-Hodgkin lymphoma (NHL) that accounts for 2-4% of NHL cases (Bhatt et al, 2015) . It generally presents with limited stage disease and a bulky anterior mediastinal mass with invasion of surrounding structures, although approximately one in four patients present with advanced stage disease (Dabrowska-Iwanicka & Walewski, 2014; Bhatt et al, 2015) . It affects predominately female patients in their third or fourth decade of life and patients can present with symptoms related to the mediastinal mass with cough, shortness of breath, pleural or pericardial effusion, or superior vena cava syndrome. Bone marrow and central nervous system involvement are usually rare (Steidl & Gascoyne, 2011; DabrowskaIwanicka & Walewski, 2014; Bhatt et al, 2015) . PMBCL has distinct clinicopathological and immunophenotypic features that distinguish it from diffuse large B-cell lymphoma (DLBCL). It is believed to arise from thymic B-cells and has a genome expression profile distinct from DLBCL but with similarities to classical Hodgkin lymphoma (HL) (Bea et al, 2005; Dabrowska-Iwanicka & Walewski, 2014) . Immunophenotyping demonstrates positivity for CD19, CD20 and CD22. Weak CD30 expression is common in PMBCL although not mandatory for the diagnosis. Additionally, PMBCL has genetic alternations in the 9p24.1 locus leading to overexpression of PD-1 (also termed PDCD1), which is not seen in DLBCL (Steidl & Gascoyne, 2011; Dabrowska-Iwanicka & Walewski, 2014) . PMBCL is characterized by medium to large-sized cells that occasionally resemble Reed-Sternberg cells with a background of sclerosis. The diagnosis of PMBCL is challenging due to overlapping lymphomatous diseases that can present with similar clinicopathological features (Steidl & Gascoyne, 2011) .
Given the rarity of PMBCL, the general treatment approach has been similar to established therapeutic algorithms for DLBCL (NCCN, 2016) . Rituximab cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been the historical standard treatment approach for PMBCL with outcomes that have been felt to be superior to those in DLBCL (Savage, 2006; Savage et al, 2006; Bhatt et al, 2015) . In addition to chemotherapy, consolidative radiation has been used due to the bulky and localized nature of this disease. The value of rituximab was validated in a prospective study that demonstrated an improved 3-year event-free survival (EFS) with the addition of rituximab to a CHOP-like regimen (Rieger et al, 2011) . Several studies have evaluated R-CHOP with similar long-term outcomes. In three retrospective studies the outcomes for R-CHOP yielded a 5-year overall survival (OS) of 81% (N = 19) , 5-year time to progression of 78% (N = 96) (Savage et al, 2012) , and a 4-year progression-free survival (PFS) of 71% (N = 187) (Aoki et al, 2014) . The role of adjuvant radiation therapy after induction chemotherapy remains controversial, although studies have suggested a benefit to this intervention (Jackson et al, 2016a,b) . Two recent large retrospective database studies from the Surveillance, Epidemiology, and End Results (SEER) (Jackson et al, 2016a) and National Cancer Databases (NCDB) (Jackson et al, 2016b) found that the addition of radiation therapy to chemotherapy provided a survival benefit in PMBCL. While the SEER study included some patients in the pre-rituximab period , the NCDB study was performed on patients in the post-rituximab period , suggesting that radiation may be beneficial even after the introduction of rituximab (Jackson et al, 2016a,b) .
More recently, a phase II study from the National Cancer Institute (NCI) demonstrated the effectiveness of a chemotherapy alone approach using the dose-adjusted (DA) R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) regimen in the treatment of PMBCL (Dunleavy et al, 2013) . In this single-arm study of 51 patients, DA-R-EPOCH showed a remarkable EFS of 93%, with a median follow-up time of 5 years. In the same study, outcomes from a separately analysed retrospective cohort (N = 16) from Stanford University showed an EFS of 100% at a median follow-up of 3 years. Given the excellent outcomes seen in this study, many physicians adopted this regimen without consolidative radiation therapy as a front-line option for PMBCL. A large, randomized prospective trial, CALBG/Alliance 50303, was performed to determine the benefit of DA-R-EPOCH over R-CHOP in large cell lymphoma. This demonstrated no difference in EFS and OS between the two regimens in patients with DLBCL and a small subset with PMBCL (N = 28) (Wilson et al, 2016) . Additionally, there was increased toxicity among DA-R-EPOCH treated patients in the form of neutropenic fevers, cytopenias and neuropathy. Due to limited sample size, results were not reported specifically for the PMBCL subgroup, leaving the question of intensity of chemotherapy unanswered. In our study, we compare outcomes by frontline regimen R-CHOP versus (vs.) DA-R-EPOCH for the treatment of PMBCL.
Patient and methods

Study design and patient population
We performed a retrospective, multicentre analysis of patients aged ≥18 years diagnosed with PMBCL between 1 January 2011 and 1 June 2016. Patients were identified at their local contributing centres via clinical databases and deidentified data was submitted to the coordinating centre at the Medical College of Wisconsin. All sites were approved by their local institutional review board and data-use agreements were in place for the submission of data to the coordinating centre. Patients were divided by frontline treatment regimen, R-CHOP versus DA-R-EPOCH. Patient-level data included age, sex, body mass index (BMI), stage, presence of "B" symptoms or bulky disease, International Prognostic Index (IPI), and Eastern Cooperative Oncology Group (ECOG) performance score at time of treatment initiation.
Our primary endpoint was OS of patients with PMBCL treated by frontline immunochemotherapy regimen, which was calculated from the date of diagnosis to death or last follow-up. Secondary outcomes included PFS, end of treatment response [complete response (CR) versus partial response (PR) versus stable disease (SD) versus progressive disease (PD)], and use of consolidative radiation therapy. PFS was calculated from the date of diagnosis to last follow-up or an event which was defined as a treatment failure necessitating a change during induction chemotherapy, relapse after completion of therapy or death. Treatment-related complications were also reported, including rates of neutropenic fever, documented infection and hospitalizations for acute toxicities during first-line therapy. Centres assessed disease response according to the 2014 Lugano Classification with a Deauville Score of 1, 2, or 3 consistent with complete response (Cheson et al, 2014) .
Statistical analysis
Demographic characteristics of the study population were summarized using proportions for categorical variables and mean/standard deviation for continuous outcomes. Comparison by treatment group were made using chi-square test for binary and nominal variables, Wilcoxon rank-sum test for ordinal variables and t-test for numeric descriptors. Survival outcomes were described using Kaplan-Meier estimates.
Our primary analysis adjusted for three features of the data -imbalance in patient characteristics between the groups, missing covariates and within-centre clustering -via propensity scores, multiple imputation and robust variance estimates, respectively. Multiple imputation was performed using fully conditional specification to impute missing values based on the observed information. All the following analyses (including propensity score calculations) were conducted separately on each of 40 imputed datasets, and the results were combined into final estimates using Rubin's formula for variance estimation.
Propensity scores were computed using logistic regression to estimate the probability of receiving DA-R-EPOCH for each patient. The following variables were used as predictors: age, sex, stage, ECOG performance score, IPI, bulky disease, "B" symptoms, positron emission tomography (PET) staging, elevated lactate dehydrogenase, CD30 expression, albumin, total bilirubin and creatinine. The propensity scores were included in our adjusted analyses as inverse probability of receiving the treatment weights (IPTW). The IPTW weighting improved the covariate balance, moving all the intergroup standardized differences below 0Á1 in absolute value (Table SI) .
Survival outcomes (PFS and OS) were analysed using IPTW weighted Cox proportional hazards regression with no additional covariates, with robust sandwich variance estimates to account for within-centre correlation. Kaplan-Meier estimates of 24-month survival were compared using a z-test. Logistic regression via generalized estimating equations with sandwich variance estimates was used for binary outcomes (infection, neutropenic fever, hospitalization during treatment, and complete response). All analyses were performed in SAS 9.4 (SAS Institute, Cary, NC) with two-sided statistical tests and an alpha = 0.05.
Results
Demographic data
A total of 144 patients were identified from 11 contributing centres with 12 patients excluded due to treatment on a single centre clinical trial. The remaining patients received R-CHOP (N = 56) or DA-R-EPOCH (N = 76) as their frontline treatment. Among all patients, the median age was 35 years (18-77) and 76 (58%) were of female gender; this was not different between the two groups (Table I) . Most patients had stage I or II disease (70% R-CHOP and 82% DA-R-EPOCH). PET/computed tomography (CT) was used for initial staging in 79% of patients treated with R-CHOP and 73% of DA-R-EPOCH patients. At the end of treatment, use of PET/CT increased to 91% in the R-CHOP group and 90% in the DA-R-EPOCH group. There were no differences in ECOG performance score, the presence of "B" symptoms, IPI or bulky disease between the two groups. CD30 was positive in 47% of tumours from patients receiving R-CHOP and 58% from patients receiving DA-R-EPOCH (P = 0Á24) ( Table I) .
The median number of immunochemotherapy cycles received were 6 (range 3-8), and 95% of patients received 6 or more cycles of induction (91% R-CHOP, 97% R-EPOCH, P = 0Á13). Dose-escalation per protocol was conducted in 48 (63%) R-EPOCH treated patients. DA-R-EPOCH use increased in frequency after the publication of the phase II study by Dunleavy et al (2013) (Fig 1) . After April 2013, 79% of patients with PMBCL received DA-R-EPOCH chemotherapy (Table I ). Prior to that date, the majority (54%) received R-CHOP chemotherapy (P < 0Á001).
Unadjusted outcomes
Among all patients, 104/132 (79%) were in CR at the end of treatment. For patients with stage 1-2 disease, the CR rate was 79% and this was not different by induction chemotherapy regimen. The CR rate for advanced stage 3-4 disease was 73% and was also not different by frontline regimen. The CR rate was higher for patients treated with DA-R-EPOCH compared to R-CHOP (84% vs. 70%, P = 0Á046). Consolidative mediastinal radiation was more common after R-CHOP than DA-R-EPOCH (59% vs. 13%, P < 0Á001). Three patients underwent consolidative autologous transplant, two after R-CHOP and one after DA-R-EPOCH. In terms of treatmentrelated complications, patients receiving DA-R-EPOCH were more likely to develop neutropenic fever (33% vs. 13%, P < 0Á01) and need hospitalization for acute toxicities (35% vs. 16%, P = 0Á02) compared to patients treated with R-CHOP. Infection rates were higher with DA-R-EPOCH, but this was not statistically significant (Table II) . In this cohort, there were a total of 13 deaths, of which 11 were due to progressive lymphoma.
Propensity weighted outcomes
A propensity weighted analysis was used to compare OS and PFS by first-line treatment. The median follow-up time for R-CHOP treated patients was 40 months (range 7-70 months) versus 22 months (range 5-64 months) for DA-R-EPOCH patients. The median OS and median PFS were Table I . Unadjusted patient demographics (N = 132). 
DA-R-EPOCH, dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PET/CT, positron emission tomography/computed tomography; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; SD, standard deviation.
R-CHOP versus DA-R-EPOCH in PMBCL
ª 2017 John Wiley & Sons Ltd not reached in either R-CHOP or DA-R-EPOCH chemotherapy treatment arms (Fig 2) . At 24 months, 89% of patients treated with R-CHOP and 91% of patients treated with DA-R-EPOCH were alive (Table III) . Similarly, the adjusted HR for OS and PFS was not statistically significant for R-EPOCH compared to R-CHOP [OS, HR = 0Á63 (0Á19-2Á15), P = 0Á46; PFS, HR = 0Á62 (0Á24-1Á47), P = 0Á28]. The adjusted odds for CR were higher for patients treated with DA-R-EPOCH [Odds ratio (OR) = 1Á19 (1Á06-1Á34), P < 0Á01]. However, the odds of development of infection, neutropenic fever and hospitalizations for acute toxicities were higher in patients receiving DA-R-EPOCH chemotherapy (Table IV) .
Role of radiation in R-CHOP treated patients
We performed an exploratory analysis to determine the role of radiation therapy in patients who received R-CHOP chemotherapy. Among these 56 patients, 33 (59%) received consolidative radiotherapy, of which 24 (62%) were in CR.
There was no correlation in the end of treatment response (CR versus no CR) and the use of radiotherapy (P = 0Á55). We limited our survival analysis to patients in CR or PR at the end of R-CHOP (N = 45) to eliminate patients with SD or PD who were then salvaged with end of treatment radiation. Among these patients, the median OS (Fig 3) was not reached in either the R-CHOP alone or R-CHOP plus radiation group and OS was not different by end of treatment radiation therapy (P = 0Á87). Similarly, there was no significant difference in PFS (Fig 3) among patients who received radiotherapy (P = 0Á38) but there was an absolute PFS difference of approximately 7% at 2 years (95% with R-CHOP plus radiation therapy versus 88% with R-CHOP alone).
Outcomes after primary induction failure or relapse
In total, there were 24 failures of frontline treatment among the 132 patients, 13 after R-CHOP and 11 after DA-R-EPOCH. Of the 24 failures, 16 had primary refractory disease (10 R-CHOP and 6 DA-R-EPOCH) and 8 relapsed after completion of induction. Among these patients, the most common regimen used for salvage was R-ICE (rituximab, ifosfamide, carboplatin, etoposide) in 18 of 24 patients. Other treatments used included brentuximab vedotin (BV), GDP (gemcitabine, dexamethasone, cisplatin), methotrexate or cytarabine. Thirteen of these 24 patients underwent an autologous transplant. Unfortunately, despite lymphoma directed treatments, 11 of 24 patients with either primary induction failure or relapse ultimately died from progressive disease.
Discussion
PMBCL is a unique and uncommon form of aggressive NHL that is potentially curable with combination chemotherapy AE radiation therapy. Historically, treatment algorithms for this disease have adopted recommendations for DLBCL, despite the fact that histologically and by genome expression profiling PMBCL is a distinct disease (Steidl & Gascoyne, 2011) . The regimen of R-CHOP AE radiation therapy had been the standard approach for PMBCL in the United States (Savage, 2006; Rieger et al, 2011) . However, after results of a phase II, single arm study of DA-R-EPOCH chemotherapy became available (Dunleavy et al, 2013) , both the induction chemotherapy regimen and the indication for end of treatment radiation have been challenged. Among the 67 patients
Progression Free Survival by Frontline Chemotherapy Regimen
Overall Survival by Frontline Chemotherapy Regimen DA-R-EPOCH, dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival. Table IV . Adjusted analysis DA-R-EPOCH treated patients. who were treated with DA-R-EPOCH in the NCI study, only 2 patients received radiation, suggesting that a more intensive induction regimen can obviate the need for this modality of treatment (Dunleavy et al, 2013) . As a result, DA-R-EPOCH without radiation has become a favoured induction regimen for PMBCL. This trend was seen in our study with a statistically significant increase in DA-R-EPOCH use after publication of the phase II study in April 2013 (Fig 1) and correlates with the shorter median follow-up time with DA-R-EPOCH patients. This finding highlights the significant influence that publications in high impact journals, such as the New England Journal of Medicine, have on the clinical practice of providers even in the setting of a non-randomized single arm study.
Overall Survival of R-CHOP Treated Patients by Consolidative Radiation Progression Free Survival of R-CHOP Treated Patients by Consolidative Radiation
The role of intensity in induction chemotherapy for PMBCL has been debated for many years. With a lack of randomized control trials in this rare histology, clinical decision-making has largely been made based on the balance of toxicity and efficacy of individual regimens. However, many studies have suggested that a more intensive induction may lead to improved outcomes. In a retrospective review of patients in the pre-rituximab era, there was a statistically significant improvement in outcomes among patients receiving a high intensity regimen with either MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine and bleomycin) or autologous stem cell transplant compared to CHOPlike inductions. A group in Italy published outcomes of MACOP-B plus involved-field radiation therapy in 53 consecutive patients. The 5-year disease-free survival was 93Á4%, in line with outcomes reported by Dunleavy et al (2013) with DA-R-EPOCH chemotherapy (Mazzarotto et al, 2007) . More contemporary high intensity combinations have included dose-dense R-CHOP followed by R-ICE consolidation. In a report of 54 patients treated with this regimen, the median PFS was 78% but despite intensified treatment, 11 patients failed therapy (Moskowitz et al, 2010) . Part of the push for higher intensity regimens for PMBCL have been based on reports of inadequacy with CHOP-based induction chemotherapy. In a retrospective review of 63 patients treated with R-CHOP AE consolidative radiation, there was a high primary induction failure rate (21%) (Soumerai et al, 2014) . Despite these data suggesting R-CHOP is inadequate, several other studies have shown that R-CHOP yields more encouraging results. In a recent review of 80 PMBCL patients, those who received R-CHOP (N = 45) had excellent outcomes with a projected 10-year PFS of 95%, however, 41 of these 45 patients did receive consolidative radiation (Lisenko et al, 2017) . In a large prospective trial comparing CHOP to R-CHOP among 80 PMBCL patients, the addition of rituximab decreased the risk of progression by 10-fold (from 24% to 2Á5%), and the reported 3-year EFS was 78% for the R-CHOP arm (Rieger et al, 2011) . Lastly, in retrospective review of 66 patients treated with R-CHOP AE consolidative radiation, the 5-year freedom from progression was 81% (Vassilakopoulos et al, 2012) .
We aimed to compare contemporary outcomes for PMBCL in patients treated after 2011 with R-CHOP versus DA-R-EPOCH chemotherapy in the "real" world setting. To our knowledge, this is the first study to evaluate patients using this approach. We used a propensity weighted analysis to control for potential confounders or predictors of treatment choice as this was not a randomized control trial. In our adjusted analysis, while OS and PFS were similar, the hazard ratio for DA-R-EPOCH chemotherapy was in favour of this more intensive regimen at both endpoints, although it did not reach statistical significance. Additionally, the CR rate was higher among DA-R-EPOCH treated patients (84% vs. 70%) and the use of radiation therapy was considerably lower with only 10/76 (13%) DA-R-EPOCH treated patients receiving consolidative radiation. Limiting radiation use can spare patients from both short-term and long-term toxicities which include secondary cancers, lung fibrosis, premature coronary artery disease and pulmonary/cardiac dysfunction (Hodgson, 2011; Chargari et al, 2013) . Our DA-R-EPOCH survival outcomes are corroborated by a recent abstract that retrospectively reviewed outcomes with DA-R-EPOCH chemotherapy alone for PMBCL. In this study of 156 patients (38 children and 118 adults), the 3-year EFS was 85Á9% (Roth et al, 2017) , similar to our findings. Consistent with other published trials (Wilson et al, 2016) , DA-R-EPOCH was complicated by more short-term treatmentrelated complications and in our adjusted analysis, there was an increased risk of hospitalizations, neutropenic fever and infection with this more intensive induction.
To determine the role of radiation therapy among R-CHOP treated patients, another area of controversy, we performed an exploratory analysis among this subset. While there was no difference in OS, there was a small absolute difference in PFS at 2 years which did not achieve statistical significance, possibly due to the small number of patients in this sub-analysis. However, these results, in addition to recent database analyses by Jackson et al (2016a,b) suggest that consolidative radiation should continue to be considered in R-CHOP treated patients. The strength of this conclusion, however, is limited by the lack of randomized, prospective data demonstrating its benefit. It is possible that, in the near future, advanced imaging with PET/CT may serve as a disease assessment tool to determine the need for end of treatment radiation therapy. In one large prospective study of PET/CT for disease assessment in PMBCL, patients with a Deauville 1-3 at end of treatment had a 5-year PFS of 99% (Martelli et al, 2014) . While many of these patients received consolidative radiotherapy, it is possible that PET/CT negative patients may represent a group that benefits less from mediastinal radiation (Martelli et al, 2014) . Supporting this hypothesis were the results of a retrospective review of 147 patients, which demonstrated no significant difference in local relapse among patients with negative PET/CT scans at the end of treatment with or without consolidative radiation (Vassilakopoulos et al, 2016) . Ultimately, the results of an R-CHOP versus DA-R-EPOCH in PMBCL ª 2017 John Wiley & Sons Ltd ongoing randomized controlled clinical trial (NCT01599559) will help determine the role of consolidative radiation in patients with PMBCL.
While the optimal regimen for PMBCL remains debatable, our results suggest that both R-CHOP and DA-R-EPOCH are highly effective frontline choices. It is possible that the addition of novel agents or targeted therapeutics may change the paradigm for treatment. Given that PMBCL patients typically express CD30, a phase II study of single-agent BV in PMBCL was performed. The results were disappointing, with only 2 partial responses out of 15 treated patients (Zinzani et al, 2017) . As PMBCL demonstrates overexpression of PD-1, the efficacy of pembrolizumab was tested in 10 patients, resulting in an overall response rate of 44% (Zinzani et al, 2015) . Currently, neither BV nor pembrolizumab are prescribed as part of frontline treatment outside of clinical trials.
There are several limitations in our study. Given the rarity of this disease, the study is limited by sample size, despite the inclusion of 11 academic centres. One must also acknowledge that, as a retrospective study, there may be institutional biases in patient population and selection of chemotherapy regimen. While we tried to adjust for measured confounders using a propensity weighted analysis, unmeasured variables could influence our findings. Pathology specimens were not centrally reviewed for accuracy but all participating centres were tertiary referral centres with dedicated haematopathologists. Lastly, we have limited data on long-term safety and efficacy of the two induction regimens. This is an important question because there are long-term risks of both mediastinal irradiation and addition of etoposide, which has been implicated in the development of therapy-related myeloid neoplasms, particularly KMT2A (MLL) rearranged acute myeloid leukaemia, a poor prognostic malignancy (Ezoe, 2012) . Longer follow-up is indicated to determine the long-term toxicity profiles of both regimens.
In conclusion, in this large, multi-centre cohort analysis, both R-CHOP and DA-R-EPOCH demonstrated excellent 2-year OS (89% and 91% respectively) in PMBCL. While there were higher CR rates with DA-R-EPOCH, patients administered this regimen were more likely to experience short-term treatment-related toxicities but were spared long-term risks associated with mediastinal radiotherapy. In the current era, consideration of early and late toxicities will be important in determining the appropriate frontline treatment regimen for patients with newly diagnosed PMBCL.
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